Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure

Oddmund Nestegard, Behrouz Moayeri, Fred-Arne Halvorsen, Tor Tønnesen, Sveinung Wergeland Sørbye, Eyvind Paulssen, Kay-Martin Johnsen, Rasmus Goll, Jon Ragnar Florholmen, Kjetil K Melby, Oddmund Nestegard, Behrouz Moayeri, Fred-Arne Halvorsen, Tor Tønnesen, Sveinung Wergeland Sørbye, Eyvind Paulssen, Kay-Martin Johnsen, Rasmus Goll, Jon Ragnar Florholmen, Kjetil K Melby

Abstract

Background: Increasing prevalence of antibiotic resistance especially to clarithromycin and metronidazole has been observed in Helicobacter pylori (H. pylori).

Aim: To characterize the antimicrobial resistance pattern of H. pylori before and after treatment in a cohort of patients accumulated over a period of 15 years after an unsuccessful eradication treatment had been given comparing sensitivity data from patients with newly diagnosed H. pylori infection. A specific objective was to look for resistance to levofloxacin.

Material and methods: Total of 50 patients newly diagnosed for H. pylori infection treated with omeprazole and amoxicillin/clarithromycin and 42 H pylori treatment-resistant patients treated with omeprazole and amoxicillin/levofloxacin were enrolled in this study. Cultures including antibiotic sensitivity testing were conducted according to standard laboratory routines and thus also in keeping with a European study protocol using E-test gradient strips or disc diffusion methods.

Results: Clarithromycin resistance was more frequently observed in the H. pylori resistant group than in newly diagnosed H. pylori group (39% versus 11%). Regarding metronidazole the distribution was 70% versus 38%, and 8% versus 12% were resistant to tetracycline. No resistance was observed for amoxicillin. After re-treatment of patients belonging to the H. pylori treatment-resistant group, just two patient strains were recovered of which one harbored metronidazole resistance. In the group of newly diagnosed H. pylori, seven patients were culture positive by control after treatment. Two and three patient strains showing resistance to clarithromycin and metronidazole, respectively. None of the strains in our material was classified as resistant to amoxicillin and levofloxacin. Whereas 12% was resistant to tetracycline in the newly diagnosed before treatment.

Conclusion: Clarithromycin resistance was more frequent in the H. pylori treatment-resistant group than strains from patients with newly diagnosed H. pylori infection. No resistance was observed to amoxicillin and levofloxacin. In such cases Therefore levofloxacin may be used provided in vitro sensitivity testing confirms applicability.

Trial registration: ClinicalTrials.gov identifier: NCT05019586.

Conflict of interest statement

There are not any commercial affiliations or competing interests in our study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

References

    1. Warren J. R. & Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet (London, England) 1, 1273–1275 (1983).
    1. Nomura A., Stemmermann G. N., Chyou P. H., Perez-Perez G. I. & Blaser M. J. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Annals of internal medicine 120, 977–981 (1994). doi: 10.7326/0003-4819-120-12-199406150-00001
    1. Go M. F. Review article: natural history and epidemiology of Helicobacter pylori infection. Alimentary pharmacology & therapeutics 16 Suppl 1, 3–15 (2002). doi: 10.1046/j.1365-2036.2002.0160s1003.x
    1. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench Spring, 8 Suppl 1, S6–S14 (2015).
    1. Breckan RK, Paulssen EJ Asfeldt AM, Kvamme JM, Straume B, Florholmen J, The All-Age Prevalence of Helicobacter pylori Infection and Potential Transmission Routes. A Population-Based Study Helicobacter 21, 586–595 (2016). doi: 10.1111/hel.12316
    1. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O’Morain C, et al.. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1, 138–144 (1996). doi: 10.1111/j.1523-5378.1996.tb00027.x
    1. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20, 280–322 (2007). doi: 10.1128/CMR.00033-06
    1. Malfertheiner P, Megraud F, O’Morain C, et al.. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56,772–81 (2007). doi: 10.1136/gut.2006.101634
    1. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26, 343–57 (2007). doi: 10.1111/j.1365-2036.2007.03386.x
    1. Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS 121, 353–358 (2013). doi: 10.1111/apm.12009
    1. Malfertheiner P, Megraud F, O’Morain CA. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report Gut 66, 6–30 (2017). doi: 10.1136/gutjnl-2016-312288
    1. Katelaris P, Katelaris A. A prospective evaluation of levofloxacin based triple therapy for refractory Helicobacter pylori infection in Australia. Intern Med J 47, 761–766 (2017). doi: 10.1111/imj.13432
    1. Nestegard O, Johnsen KM, Sørbye S, Halvorsen FA, Tønnessen T, Paulssen E, et al.. Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication. PLOS ONE 15(9): e0238944 (2020). doi: 10.1371/journal.pone.0238944
    1. Mégraud F, Alix C, Charron P, Bénéjat L, Ducournau A, Bessède E, et al.. Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter 26(1); e12767 (2021). doi: 10.1111/hel.12767
    1. Alba C, Blanco A, Alarcon T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis 30:489–497 (2017). doi: 10.1097/QCO.0000000000000396
    1. Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol 14, 383–384 (2017). doi: 10.1038/nrgastro.2017.57
    1. Antibiotic usage ESDC report 2015 Annual reports and protocols on antimicrobial consumption () (2015).
    1. Malfertheiner P, Megraud F, O’Morain C, et al.. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 9 (1), 1–2 (1997). doi: 10.1097/00042737-199701000-00002
    1. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al.. Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1):34–42 (2013). doi: 10.1136/gutjnl-2012-302254
    1. Steinbakk M, Moyeri B, Melby KK. Antibiotic sensitivity pattern in Helicobacter pylori from previously untreated patients in South-Eastern Norway 2018. (Poster) Nordic Soc Antimicrob Resistance Conference, Trondheim, Norway 2018. (Melbye KK, personal communication).
    1. The National Prescription-Based Medicines Register (Prescription Register) Prescription Norwegian Database/reseptregister.data@fhi.no.
    1. Nichols AG, et al. on the behalf of the Hp-EuReg Investigators. Pan-European Registry on H.pylori Management (Hp-Eu-Reg): Bacterial resistance of 2241 H.pylori isolates. Helicobacter 22 (Suppl 1), 56 (2017.
    1. Asfeldt AM, Løchen ML, Straume B, Steigen SE, Florholmen J, Goll R, et al.. Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection. Scand J Gastroenterol 39, 1073–7 (2004). doi: 10.1080/00365520410007944
    1. Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of Helicobacter pylori in Iceland. Infect Dis (Lond) 49, 647–654 (2017). doi: 10.1080/23744235.2017.1317359
    1. Salehi N, Attaran B, Eskini N, Esmaeili M, Sharifirad A, Sadeghi M, et al..—New insights into resistance of Helicobacter pylori against third and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter. 2019;24(5):e12628. doi: 10.1111/hel.12628
    1. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli M. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterolgy 155, 1372–1382 (2018). doi: 10.1053/j.gastro.2018.07.007
    1. Smith SM, Colm O’Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 35, 6–13 (2019). doi: 10.1097/MOG.0000000000000497
    1. Crowe SE. Helicobacter pylori Infection. N Eng J Med 380, 1158–1165 (2019).

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit